Hepatitis B Therapies

Manufacturing Agreement Signed for New Formulation of H-BIG

Published in Blood Weekly, November 3rd, 1997

Nabi announced it has entered into an agreement with Cangene Corporation for the manufacture of a new formulation of H-BIG, Nabi's product to prevent hepatitis B infection.

The agreement reflects Nabi's recent activities to further ensure a reliable source of H-BIG, the market's leading therapeutic for hepatitis B infection.

Cangene's manufacturing process of H-BIG will include dual viral inactivation steps using state-of-the-art technology to produce products with the highest safety standards currently available.

Under the terms of the agreement with Cangene, Cangene will manufacture H-BIG for at least three years once the new...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-11-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry